Zhou Chuan-Guo, Zhang Yong, Li Hui, Liu Ke-Yun, Yang Xiang-Yu, Gao Kun
Department of Interventional Radiology, Beijing Chaoyang Hospital, The Affiliated Hospital of Capital Medical University, Beijing 100020, China.
World J Gastrointest Surg. 2025 Aug 27;17(8):108579. doi: 10.4240/wjgs.v17.i8.108579.
No reports have been published on the use of iodine-125 (I) seed strips combined with double biliary self-expandable metallic stent (SEMS) for the treatment of type III and IV hilar malignant biliary obstruction (MBO).
To evaluate effectiveness and safety of I seed trips combined with double SEMS in treating Bismuth type III and IV hilar MBO.
This was a retrospective, observational study conducted from April 2017 to December 2022. Patients with Bismuth-Corlette type III and IV hilar MBO who underwent I seed strip implantation combined with double SEMS placement were analyzed. Patient demographics, clinical characteristics, SEMS implantation methods, procedural and clinical outcomes, overall survival, stent patency duration, and complications were evaluated.
Four types of stent implantation were utilized: (1) Type X; (2) Type T; (3) Type Y; and (4) Tandem type. The technical success rate was 94.1% (16/17), and the clinical success rate was 100% (17/17). The median overall survival time was 189.00 days ± 47.27 days (95%CI: 96.35-281.66). The median stent fluency time was 154.00 days ± 12.19 days (95%CI: 130.11-177.89). No serious complications were observed.
This retrospective, observational study suggests that the combination of I seed strips with double SEMS may be a safe and potentially effective approach for managing type III and IV hilar MBO patients.
关于碘 - 125（I）籽源条联合双胆道自膨式金属支架（SEMS）治疗III型和IV型肝门部恶性胆管梗阻（MBO）的报道尚未发表。
评估I籽源条联合双SEMS治疗Bismuth III型和IV型肝门部MBO的有效性和安全性。
这是一项于2017年4月至2022年12月进行的回顾性观察研究。分析了接受I籽源条植入联合双SEMS置入的Bismuth - Corlette III型和IV型肝门部MBO患者。评估了患者的人口统计学特征、临床特征、SEMS植入方法、手术和临床结果、总生存期、支架通畅持续时间及并发症。
采用了四种类型的支架植入方式：（1）X型；（2）T型；（3）Y型；（4）串联型。技术成功率为94.1%（16/17），临床成功率为100%（17/17）。中位总生存时间为189.00天±47.27天（95%CI：96.35 - 281.66）。中位支架通畅时间为154.00天±12.19天（95%CI：130.11 - 177.89）。未观察到严重并发症。
这项回顾性观察研究表明，I籽源条联合双SEMS可能是治疗III型和IV型肝门部MBO患者的一种安全且可能有效的方法。
